# RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome

> **NCT03684564** · PHASE2 · UNKNOWN · sponsor: **University College, London** · enrollment: 43 (actual)

## Conditions studied

- Antiphospholipid Syndrome
- Systemic Lupus Erythematosus
- Stroke
- Ischemic Stroke
- Brain Ischemia

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT03684564
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-09
- **Primary completion:** 2025-02
- **Final completion:** 2025-08
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2023-12-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03684564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03684564, "RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03684564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*